Eton Pharmaceuticals launches IMPAVIDO (miltefosine) in U.S., its 11th commercial rare disease product

Eton Pharmaceuticals, Inc.

U.S. commercial launch of IMPAVIDO (miltefosine) capsules; Eton holds exclusive U.S. commercialization rights for the antileishmanial therapy.
IMPAVIDO is indicated for visceral, cutaneous and mucosal leishmaniasis in adults and adolescents at least 12 years old weighing 30 kg (66 lbs) or more.
Eton Cares patient support includes $0 co-pay for eligible commercially insured patients and expanded patient assistance programs.
Distribution via Anovo Specialty Pharmacy (e-prescribe Anovo #5 Memphis; referral fax 855-813-2039; line 877-469-4078); hospital consignment stocking and emergency access pathway.
Eton now lists eleven commercial rare disease products, including KHINDIVI, INCRELEX, ALKINDI SPRINKLE and IMPAVIDO, plus five late-stage candidates (AMGLIDIA, ASN-001, ET-700, ET-800, ZENEO).

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.